Aims: To evaluate the role of free fatty acid receptor 2 (FFAR2)/G-protein coupled receptor 43 in mediating the effects of the short chain fatty acids (SCFAs) sodium acetate (SA) and sodium propionate (SP) on islet function in vitro, and to identify the intracellular signalling pathways used in SCFA-induced potentiation of glucose-induced insulin secretion.
| INTRODUCTION
Diet-derived short-chain fatty acids (SCFAs) originate from the intestinal fermentation of fibre and undigested carbohydrates by bacteria residing in the colonic lumen. 1 They consist of fatty acid chains of up to six carbons, with acetate (C2), propionate (C3) and butyrate (C4) representing the main circulating forms in the human body. 2 In recent years it has become apparent that SCFAs are the endogenous ligands for two G-protein coupled receptors (GPRs), namely free fatty acid receptor (FFAR)2 (GPR43) and FFAR3 (GPR41), 3 and that these receptors are expressed in organs playing a role in glucose homeostasis. In particular, we and others have identified that FFAR2 and FFAR3 are expressed by islets of Langerhans, [4] [5] [6] [7] opening up the possibility that SCFAs contribute to the regulation of insulin secretion through activation of these receptors. However, the data published so far do not provide a consensus role for SCFAs and their receptors in islets: the first paper published in this area reported that acetate inhibited insulin release in vitro and that deletion of FFAR2 and FFAR3
improved glucose tolerance, 7 while there have been more recent reports of SCFAs stimulating insulin secretion and of deletion of FFAR2 being associated with insufficient β-cell mass expansion in obesity and gestational diabetes. 5, 6, [8] [9] [10] [11] [12] Acetate is the most abundant circulating SCFA, reaching plasma concentrations of~200 μM, 13 while propionate concentrations are~10-fold lower, 2 and these are the two SCFAs that are used most commonly for experimental studies. They can couple to both inhibitory and stimulatory signalling through activation of FFAR2 and/or FFAR3, which differ in their downstream signalling cascades. 3, 14 Thus, while FFAR3 couples only to Gi to decrease intracellular cAMP levels, FFAR2 is able to recruit both Gi and Gq to decrease cAMP and increase diacylglycerol and inositol trisphosphate generation. We have previously demonstrated that cannabinoid receptor agonists that signal through both Gi and Gq increase insulin secretion, as the stimulatory input outweighs the reduction in cAMP production, 15, 16 and it has recently been reported that a Gq-biased FFAR2-selective agonist potentiates glucose-induced insulin secretion. 12 Consistent with this, we have reported that propionate reversibly stimulates insulin secretion from human islets through a Gq/protein kinase C (PKC)-dependent pathway. 5 Observations of stimulatory signalling in β-cells via FFAR2 contrast with the report that transgenic mice with global FFAR2 deletion show enhanced insulin secretion, which implicates pre-eminence of the Gi signalling pathway in mouse β-cells. 7 In the present study we used islets isolated from wild-type and FFAR2 −/− mice to quantify the effects of acetate and propionate on dynamic insulin secretion and to determine the roles of intracellular calcium and PKC activation in SCFA signalling in mouse islets. We also determined whether SCFAs can protect mouse islets from apoptosis induced by lipo-and cytotoxic assault, and the role of FFAR2 in this. Key experiments exploring the role of acetate on insulin secretion and islet survival were also carried using isolated human islets. 
| MATERIALS AND METHODS

| Materials
| Mice
All animal procedures were approved by the UK Home Office Animals (Scientific Procedures) Act 1986 (project licence number: 70/8068).
FFAR2 global knockout (FFAR2
−/− ) mice were obtained from Prof.
McKay at the Garven Institute, Australia. FFAR2 deletion in C57Bl/6 J mice was obtained by homologous recombination, which substitutes a 55 bp of Ffar2 exon 1 with the β-gal-neo cassette, shifting the downstream amino acid sequence out of the reading frame, and the progenies were generated through cross breeding of mice heterozygous for FFAR2 (FFAR2 +/− ). Genotypes of offspring were determined by standard PCR, as described earlier. 17 All mice were housed at 21 C to 23 C on a 12-hour light/dark cycle at Imperial College London, with food and water provided ad libitum.
| Islet isolation
Islets were isolated from FFAR2 −/− mice (aged 8-10 weeks) and agematched wild-type mice, essentially as described. 18 Islets were maintained overnight at 37 C in RPMI, supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine and 100 U/mL/0.1 mg/mL peni- 
| Quantification of FFAR3 mRNA expression
Total RNA was extracted from groups of 200 islets isolated from either wild-type or FFAR2 −/− mice using the Qiagen RNeasy Minikit, 4 then mRNA was reverse-transcribed into cDNA, which was quantified using a NanoDrop spectrophotomoter. Quantitative PCR reactions were performed on a Lightcycler 480 using 1 μg of cDNA and specific primers for FFAR3, and expression levels were normalized to Gapdh mRNA expression in the same samples. Nikon Eclipse TE2000-U microscope.
| Insulin secretion and content
Groups of 40 mouse or 50 human islets were perifused at 0.5 mL/min with a physiological salt solution, 20 were supplemented with agents of interest, and perifusate samples were collected every 2 minutes for quantification of secreted insulin. 21 In some experiments, islet PKC was downregulated by maintenance of islets for 20 hours in the presence of 200 nM 4β phorbol 12-myristate 13-acetate (PMA), and control islets were treated with the inactive phorbol ester 4α phorbol 12,13 didecanoate (PDD), 22 and in other experiments, islets were exposed to 100 ng/mL of pertussis toxin (PTX) for 18 hours to block Gi-dependent signalling. 23 objective was filtered at 510 nm and recorded with a CCD camera. 21 
| cAMP quantification
Groups of five mouse or human islets were incubated for 1 hour at 37 C in a physiological salt solution 20 containing test agents of interest and supplemented with 2 mM IBMX to inhibit phosphodiesterases. Islets were lysed and cAMP levels were quantified using a fluorescence assay, according to the manufacturer's instructions. Data were acquired using a PHERAstar FS microplate reader (100-μs delay time, 100-μs integration time, 50 flash read time).
| ATP generation
Groups of three islets were incubated for 1 hour at 37 C and ATP levels were determined by chemoluminescence with the Promega ® 3D Cell Titer-Glo assay, according to the manufacturer's instructions. 24 
| Apoptosis
Mouse or human islets were pre-cultured in complete medium in the absence or presence of propionate or acetate for 24 hours, then groups of five islets were exposed to RPMI with 2% FBS (mouse) or CMRL with 0.2% albumin (human) supplemented either with 0.5 mM sodium palmitate or a cytokine cocktail (5 U/μL TNFα, 0.5 U/μL IL-1β, 5 U/μL IFNγ) in the continued absence or presence of acetate or propionate for a further 20 hours. Palmitate was initially made as a 100 mM stock in 50% ethanol, diluted to 5 mM in 10% fatty acid-free BSA in RPMI, then further diluted in RPMI (2% FBS) to 0.5 mM for experimental use. Islet cell apoptosis was determined using the Caspase3/7 Glo assay according to the manufacturer's instructions. 5 In this assay, activation of the effector caspases 3 and 7 leads to cleavage of a proluminescent substrate, resulting in generation of a luminescent signal that was quantified using a Veritas luminometer at 450 nm.
| Statistical analysis
Static incubation data were analysed with PRISM ® Graphpad using oneway ANOVA followed by Dunnet multiple comparison test or Student's t tests, as appropriate. Perifusion secretion data were analysed by one-or two-way ANOVA with repeated measures. Differences were considered statistically significant when P values were < 0.05.
3 | RESULTS
| FFAR2 deletion does not impair mouse islet physiological characteristics
Immunohistochemical 
| Effects of SA and SP on islet second messenger generation
We have previously shown that SP increases [Ca 2+ ] i in human islets, The potential contribution of Gi-mediated signalling to the effects of SA and SP in islets was investigated by the quantification of mouse islet cAMP levels by fluorescence resonance energy transfer (FRET). Elevations in islet cAMP were induced by exposure to 1 μM forskolin in the presence of the phosphodiesterase inhibitor IBMX, and the Gi-coupled α 2 -adrenergic agonist clonidine completely suppressed cAMP production in response to forksolin ( Figure 3C ); however, under the same conditions, neither 1 mM SA nor 1 mM SP had any significant effects on islet cAMP generation, and no significant differences in cAMP levels were observed in the responses of islets from wild-type and FFAR2 −/− mice ( Figure 3C ).
As SCFAs may regulate intracellular signalling secondary to their mitochondrial metabolism their effects on islet ATP generation were also investigated. These experiments indicated that elevation in glucose concentration from 2 to 20 mM stimulated ATP levels, as expected ( Figure 3D ), but 1 mM SA or SP did not elevate basal or glucose-stimulated ATP production. Similar to the experiments in which cAMP was quantified, deletion of FFAR2 did not influence glucose-induced ATP generation in mouse islets, and nor did it modify the levels of ATP observed in the presence of SA or SP ( Figure 3D ).
3.4 | SA potentiates insulin secretion from human islets via phospholipase C/PKC-dependent pathways, but does not activate Gi-coupled signalling
Our earlier experiments investigating SCFA signalling in human islets focused on the role of SP, 5 so we extended these experiments in the present study to determine the concentration-dependent effects of the shorter SCFA, SA, on insulin secretion from isolated human islets, The stimulation of insulin release from human islets by SA is in contrast to a previous report of its Gi-mediated inhibition of glucose-stimulated insulin secretion from human islets in static incubations. 8 We therefore investigated whether SA acted via Gi in human islets by pre-treating them with 100 ng/mL PTX to ADP-ribosylate Gi and thus abolishing signalling via this pathway. As can be seen from does not act via Gi in human islets was evident from the lack of inhibitory effect of SA on intracellular cAMP levels (1 μM forskolin: 120.8 AE 11.9 nM; +1 mM SA: 144.8 AE 7.6 nM, P > 0.2; +10 μM clonidine: 79.6 AE 6.8 nM, P < 0.001, n = 6).
| SCFAs protect islets from apoptosis
The effects of SCFAs on isolated islets are not limited to improving their insulin secretory performance. Previously we established that overnight exposure of human islets to SP protects against both cytokine and palmitate-induced apoptosis, 5 and we observed that SA also had an anti-apoptotic effect in human islets in the present study Sodium acetate (SA) reversibly potentiates insulin secretion from human islets via PLC-and protein kinase C (PKC)-dependent pathways. A, Dynamic profiling of insulin secretion from human islets exposed to different concentrations of SA in the presence of 20 mM glucose. Data are expressed as mean AE SEM of n = 6 independent experiments, with four replicates per SA concentration. B, Area under the curve (AUC) data were calculated for all perifusion conditions shown in panel A. **P < 0.01, ***P < 0.001, ns P > 0.1: insulin secretion in response to SA vs control. C, Dynamic profiling of insulin secretion from human islets exposed to SA in the absence (solid circles) or presence (white circles) of the selective PLC inhibitor U73122. Data are expressed as mean AE SEM of n = 3 independent experiments, with three replicates per condition. P < 0.05: control vs U73122, insulin secretion in response to SA. D, Dynamic profiling of insulin secretion from human islets incubated for 20 hours with 200 nM 4β phorbol 12-myristate 13-acetate (PMA) to downregulate PKC (white circles), 200 nM 4α phorbol 12,13 didecanoate (PDD), an inactive phorbol ester (open squares), or under standard culture conditions (solid circles). Data are expressed as mean AE SEM of n = 3 independent experiments, with four replicates per treatment. P < 0.001: control vs PMA, insulin secretion in response to SA. E, Dynamic profiling of glucose-dependent insulin secretion from human islets pre-exposed for 18 hours to 100 ng/mL pertussis toxin (PTX; open circles) or vehicle (solid circles). Data are expressed as mean AE SEM of n = 2 independent experiments, with four replicates per treatment
| DISCUSSION
The beneficial effects of diets rich in fibre and fermentable carbohydrates on glucose homeostasis in humans has been evident for several years, 1, 2, 5, [26] [27] [28] [29] [30] and it is now recognized that dietary fermentable precursors lead to elevations in SA and SP both in the colonic lumen and in the general circulation. 5, 14 The G-protein coupled receptor FFAR2
has been implicated in the effects of SCFAs in colonic L-cells, adipocytes and immune cells to promote secretion of incretin hormones, reduce lipolysis and regulate production of immune mediators. 4, [27] [28] [29] [30] [31] [32] The demonstration of FFAR2 involvement in glucagon-like peptide-1 and peptide YY secretion from the intestine suggests that the beneficial effects of SCFAs on islets could be, at least in part, secondary to the indirect stimulatory and protective effects of these incretins on islet β cells 27, 28, 33 ; however, the presence of FFAR2 on mouse and human β cells 4-7 supports a direct role in islets for those SCFAs originating from colonic fermentation of dietary fibre and undigested carbohydrates.
Although FFAR2 and FFAR3 deletion is reported to improve glucose tolerance in obese mice, 7 it has also been reported that Our data with isolated islets build on our earlier study in which we demonstrated direct potentiation of glucose-induced insulin secretion from human islets by SP, 5 and our use in the present study of islets isolated from FFAR2 −/− mice has now allowed us to identify that SCFAs directly stimulate insulin secretion and protect against apoptosis in a FFAR2-dependent manner. In addition, we have identified that SA and SP signal in mouse and human islets via stimulatory FIGURE 5 Sodium acetate (SA) and sodium propionate (SP) protect islets from apoptosis in a FFAR2-dependent manner. A, Effects of SA on human islet apoptosis. Human islets were maintained for 20 hours in the presence of RPMI containing mixed cytokines (black bars) or cytokine-free RPMI (white bars) in the absence or presence of 1 mM SA, and apoptosis was determined by luminescence assay of caspase 3/7 activities. Data are expressed as mean + SEM, n = 8, representative of three independent experiments. *P < 0.05, **P < 0.01. B, Contribution of FFAR2 to the anti-apoptotic effects of SA and sodium palmitate (SP). Islets isolated from wild-type (upper panel) or FFAR2
−/− (lower panel) mice were maintained for 20 hours in the presence of RPMI containing mixed cytokines (black bars), sodium palmitate (grey bars) or RPMI containing 0.25% ethanol/0.5% BSA as a control for palmitate treatment (white bars) in the absence or presence of 1 mM SA or SP. Apoptosis was determined as in A and data are expressed as mean + SEM of six independent experiments, each consisting of 6-8 replicates. **P < 0.01, ***P < 0.001, ns P > 0.1.
SCFA, short chain fatty acids; WT, wild-type of action, perhaps via another Ca
2+
-dependent pathway such as activation of Ca 2+ -calmodulin-dependent kinase II. 34 The capacity of SCFAs to bind to and activate both FFAR2 and FFAR3 has led to some inconsistencies in published data, because FFAR3 couples only to Gi whereas FFAR2 couples to both Gi and Gq. 14 Inhibitory effects of SCFAs on insulin secretion have been reported, and are most likely a consequence of Gi-mediated reductions in intracellular cAMP levels. 7 Our results indicate that SCFAs do not reduce cAMP production by mouse or human islets, and the effects of SA to potentiate insulin secretion were not modified by PTX-induced inactivation of Gi signalling in human islets. The data that we obtained with PTX treatment of human islets also indicate that its abolition of the cAMP inhibitory tone does not result in an increase in basal or glucose-stimulated insulin secretion, as is observed with PTX inactivation of Gi signalling in rodent islets. 23 The reasons for this difference are not clear, but these observations suggest that tonic cAMP inhibition is more important in rodent than human islets.
It has recently become apparent that co-expression of FFAR2 and FFAR3 by cells can result in formation of FFAR2/FFAR3 heteromers in which SCFA-induced inhibition of cAMP generation is impaired and Ca 2+ signalling is enhanced. 35 It is therefore possible that FFAR2/ FFAR3 heteromers in β-cells allow SCFAs preferentially to couple to PLC activation to promote stimulatory cascades.
In addition to promoting insulin secretion we found that SA and SP also exerted anti-apoptotic actions in islets under both cytotoxic and lipotoxic conditions that mimic the physiological stresses to which islets are exposed in type 1 and type 2 diabetes.
The use of islets from FFAR2 −/− mice has allowed us to identify the important role of this receptor in transducing not only the stimulatory effects of SA and SP on insulin release, but also their protective effects against apoptotic stimuli. These data are consistent with earlier reports that FFAR2 is required for the adaptive expansion of β-cell mass during pregnancy, 28 and that the loss of FFAR2 is linked to impaired islet mass and β-cell survival. 29 Nevertheless, more studies are needed to elucidate the intracellular pathways that are activated by FFAR2 to sustain islet viability and mass expansion.
In conclusion, the present study provides important data to support a re-evaluation of FFAR2 in mediating stimulatory effects of the SCFAs SA and SP in islets. The SA-and SP-induced reversible potentiation of glucose-induced insulin secretion and protection against apoptosis are typical of an effective therapy for type 2 diabetes, and the FFAR2-dependence of these effects suggests that FFAR2 represents a potential pharmacological candidate for the treatment of impaired glucose homeostasis and type 2 diabetes.
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